Skip to main content

Table 1 Demographics of the study sample

From: The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe

 

US

EU5

Country, n (%)

 US

289 (100.0)

 EU5

 

1037 (100.0)

 France

347 (33.5)

 Germany

379 (36.5)

 Italy

55 (5.3)

 Spain

171 (16.5)

 UK

85 (8.2)

Age, years

 Mean (SD)

42.9 (14.9)

39.2 (13.8)

Sex, n (%)

 Male

148 (51.2)

577 (55.6)

 Female

141 (48.8)

460 (44.4)

Duration since diagnosis, years

 Mean (SD)

6.4 (7.0)

5.3 (5.9)

Body mass index

 Mean (SD)

25.7 (4.7)

24.0 (4.2)

Smoking status, n (%)

 Current smoker

23 (8.3)

151 (16.0)

 Ex-smoker

88 (31.7)

295 (31.2)

 Never smoked

167 (60.1)

499 (52.8)

Comorbidities, n (%)a

 Hypertension

73 (25.3)

111 (10.7)

 Anxiety

54 (18.7)

110 (10.6)

 Hyperlipidemia

46 (15.9)

69 (6.7)

 Depression

33 (11.4)

55 (5.3)

 Diabetes (with or without chronic complications)

21 (7.3)

30 (2.9)

 Osteoarthritis

15 (5.2)

25 (2.4)

 Anemia

10 (3.5)

61 (5.9)

 Osteoporosis

9 (3.1)

24 (2.3)

Charlson Comorbidity Index score

 Mean (SD)

0.2 (0.6)

0.2 (0.6)

  1. Abbreviations: DSP Disease Specific Programme, EU5 European Union 5 (France, Germany, Italy, Spain, the UK), SD standard deviation, UK United Kingdom, US United States
  2. aOnly comorbidities that appear in > 2% of patients in either the US or EU5 are reported. Note that because multiple years of the DSP database were integrated into this analysis, comorbidities were not always assessed consistently in all patients. The percentages reflect the number of patients with a given comorbidity divided by the total number of patients who were assessed for that comorbidity (which may be lower than the total sample size in some cases)